ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,522,106 | +15.0% | 12,085 | -14.5% | 0.29% | +3.5% |
| Q3 2023 | $1,323,601 | +23.1% | 14,135 | +17.4% | 0.28% | +31.6% |
| Q2 2023 | $1,074,838 | -17.8% | 12,043 | -1.3% | 0.22% | -43.0% |
| Q1 2023 | $1,308,191 | -18.9% | 12,201 | -7.6% | 0.38% | -75.9% |
| Q4 2022 | $1,613,337 | +15.8% | 13,210 | -2.1% | 1.56% | +22.4% |
| Q3 2022 | $1,393,000 | 0.0% | 13,495 | -10.0% | 1.28% | +20.7% |
| Q2 2022 | $1,393,000 | -21.0% | 14,987 | -0.3% | 1.06% | +27.6% |
| Q1 2022 | $1,764,000 | -23.8% | 15,027 | -12.7% | 0.83% | -1.4% |
| Q4 2021 | $2,316,000 | – | 17,216 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |